New pill takes aim at Hard-to-Treat cancers
NCT ID NCT06586957
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests an experimental oral drug called NKT3964 in adults with advanced or metastatic solid tumors that have not responded to standard treatments. The drug works by degrading a protein (CDK2) that helps cancer cells grow. The study has two parts: first, finding a safe dose, and then testing how well that dose shrinks tumors in specific cancers like ovarian, endometrial, breast, gastric, and lung cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- NKT3964 (an oral drug that degrades CDK2 protein to slow cancer growth)
- What this could lead to
- If successful, this could lead to a new oral treatment option for certain advanced solid tumors, especially those with CCNE1 amplification.
- What could go wrong
- This is an early Phase 1 trial with only 150 participants, so safety and effectiveness are not yet proven. The drug may cause side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED ENDOMETRIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
AdventHealth Cancer Institute
RECRUITINGOrlando, Florida, 32804, United States
-
Augusta University
NOT_YET_RECRUITINGAugusta, Georgia, 30912, United States
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
-
Emory Winship Cancer Institute
RECRUITINGAtlanta, Georgia, 30322, United States
-
Florida Cancer Specialists & Research Institute
TERMINATEDLake Mary, Florida, 32746, United States
-
Intermountain Health
RECRUITINGSalt Lake City, Utah, 84145, United States
-
John Theurer Cancer Center at Hackensack UMC
RECRUITINGHackensack, New Jersey, 07601, United States
-
NEXT Oncology
RECRUITINGAustin, Texas, 78758, United States
-
NEXT Virginia
RECRUITINGFairfax, Virginia, 22031, United States
-
SCRI at HealthOne
RECRUITINGDenver, Colorado, 80218, United States
-
Sarah Cannon Research Institute (SCRI)
RECRUITINGNashville, Tennessee, 37203, United States
-
Sidney Kimmell Cancer Center - Jefferson Health
RECRUITINGPhiladelphia, Pennsylvania, 19107, United States
-
UCSF
WITHDRAWNSan Francisco, California, 94158, United States
-
UPMC
WITHDRAWNPittsburgh, Pennsylvania, 15213, United States
-
UT Southwestern
RECRUITINGDallas, Texas, 75235, United States
Contact Email: •••••@•••••
-
University of Arkansas Medical School
RECRUITINGLittle Rock, Arkansas, 72205, United States
-
University of California - Los Angeles
NOT_YET_RECRUITINGLos Angeles, California, 90095, United States
-
University of Kansas
WITHDRAWNFairway, Kansas, 66205, United States
-
University of Virginia
RECRUITINGCharlottesville, Virginia, 22903, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Can a new drug shield nerves from Chemotherapy's side effects?
- Can your own immune cells beat advanced cancer?
- Can a simple blood test spot ovarian cancer before it starts?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can a Tumor's DNA guide better cancer care for kids?